Kiwi Wealth Investments Limited Partnership bought a new position in shares of Agilent Technologies Inc (NYSE:A) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,458 shares of the medical research company’s stock, valued at approximately $773,000.
Several other hedge funds have also recently bought and sold shares of the business. BOKF NA grew its stake in shares of Agilent Technologies by 1.4% in the 4th quarter. BOKF NA now owns 11,229 shares of the medical research company’s stock worth $757,000 after buying an additional 158 shares during the last quarter. American International Group Inc. grew its stake in shares of Agilent Technologies by 10.0% in the 4th quarter. American International Group Inc. now owns 142,485 shares of the medical research company’s stock worth $9,612,000 after buying an additional 12,904 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Agilent Technologies by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,234,035 shares of the medical research company’s stock worth $285,139,000 after buying an additional 285,330 shares during the last quarter. Captrust Financial Advisors grew its stake in shares of Agilent Technologies by 2,121.1% in the 4th quarter. Captrust Financial Advisors now owns 422 shares of the medical research company’s stock worth $29,000 after buying an additional 403 shares during the last quarter. Finally, Kinneret Advisory LLC purchased a new stake in shares of Agilent Technologies in the 4th quarter worth approximately $3,708,000.
In related news, VP Rodney Gonsalves sold 6,155 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $79.79, for a total value of $491,107.45. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Dominique Grau sold 7,711 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $80.00, for a total value of $616,880.00. Following the completion of the transaction, the insider now directly owns 102,196 shares in the company, valued at $8,175,680. The disclosure for this sale can be found here. Insiders have sold a total of 74,171 shares of company stock worth $5,764,185 over the last three months.
Several analysts have commented on A shares. Alembic Global Advisors downgraded Agilent Technologies to a “hold” rating in a research note on Monday, December 31st. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a research note on Monday, January 21st. Needham & Company LLC started coverage on Agilent Technologies in a research note on Wednesday, January 2nd. They set a “buy” rating and a $77.00 target price on the stock. JPMorgan Chase & Co. increased their target price on Agilent Technologies to $85.00 and gave the company an “overweight” rating in a research note on Thursday, February 21st. Finally, Bank of America reiterated a “buy” rating and set a $87.00 target price (up from $78.00) on shares of Agilent Technologies in a research note on Thursday, February 21st. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $86.40.
NYSE A opened at $80.61 on Friday. The firm has a market cap of $25.38 billion, a PE ratio of 28.89, a PEG ratio of 2.22 and a beta of 1.38. The company has a current ratio of 3.39, a quick ratio of 2.79 and a debt-to-equity ratio of 0.36. Agilent Technologies Inc has a 1-year low of $60.42 and a 1-year high of $81.76.
Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, February 20th. The medical research company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.03. The firm had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Agilent Technologies had a return on equity of 19.90% and a net margin of 22.86%. The company’s revenue was up 6.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.66 EPS. As a group, analysts forecast that Agilent Technologies Inc will post 3.06 EPS for the current fiscal year.
Agilent Technologies declared that its Board of Directors has approved a share buyback program on Monday, November 19th that authorizes the company to repurchase $1.75 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 8.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.
COPYRIGHT VIOLATION WARNING: This piece was first published by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.fairfieldcurrent.com/news/2019/03/15/kiwi-wealth-investments-limited-partnership-invests-773000-in-agilent-technologies-inc-a.html.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Receive News & Ratings for Agilent Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Agilent Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.